Skip to main content

New NF1 Plexiform Neurofibroma Gleevec Trial Opens

By June 14, 2010December 5th, 2023Awareness

There have been some positive reports from pilot use of the drug Gleevec (Imatinib Mesylate) in NF1 plexiform neurofibromas. Now a second pilot study of Gleevec for treatment of plexiforms has been announced and is open for recruitment at Indiana University. This is an interventional, open-label study (i.e. no placebo arm – if you participate you will receive drug). The study needs 20 patients aged 18-65. For more information on the trial including eligibility criteria for participation, click here or got to and search ‘neurofibromatosis’ for a list of all currently trials accepting those with neurofibromatosis.